We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Novel Device Reduces Blood Draw Contamination

By LabMedica International staff writers
Posted on 01 Jun 2017
A novel device can significantly reduce contamination of blood cultures, potentially reducing risky overtreatment and unnecessary use of antibiotics for many patients. This approach could also substantially reduce healthcare costs.

Thousands of patients get their blood drawn every day for blood cultures in order to diagnose serious infections such as sepsis, which can be a deadly condition. A small but significant percentage of the blood cultures are contaminated, due in part to skin fragments containing bacteria that are dislodged during a blood draw.

Scientists at the University of Nebraska Medical Center conducted a prospective, controlled study with 904 patients and 1,808 blood cultures and compared the standard procedure to an initial specimen diversion device (ISDD) to determine whether blood culture contamination was reduced. The sterile blood collection system diverts and sequesters the first 1.5 to 2 mL of blood, which often carries contaminating skin cells and microbes and this part of the blood is discarded.

The team used the SteriPath initial specimen diversion device and were able to decrease the false positive rate significantly through use of this device, from 1.78% down to 0.2%, which represents an 88% reduction. Contamination rates routinely range from 0.6% to 6% in health care institutions the USA. Costs associated with blood culture contamination per patient case ranged from USD 1,000 in 1998 to USD 8,700 in 2009. A more recent study in the USA observed excess charges of USD 8,720 per contamination event.

Mark Rupp, MD, professor and lead author of the study, said, “A lot of people think this is a minor problem. However, contaminated blood cultures are a big deal. Physicians can be led astray and patients may be harmed by additional tests and unnecessary antimicrobial therapy. What is important about this device is it can greatly limit the blood culture from being contaminated, so physicians are rarely fooled by false-positive results. It gives clinicians confidence that results are accurate.” The study was published on in the journal Clinical Infectious Diseases.


New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
Verification Panels for Assay Development & QC
Seroconversion Panels
New
Troponin I Test
Quidel Triage Troponin I Test
New
TORCH Infections Test
TORCH Panel
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: The experimental blood test accurately indicates severity and predicts potential recovery from spinal cord injury (Photo courtesy of 123RF)

Blood Test Identifies Multiple Biomarkers for Rapid Diagnosis of Spinal Cord Injury

The National Institutes of Health estimates that 18,000 individuals in the United States sustain spinal cord injuries (SCIs) annually, resulting in a staggering financial burden of over USD 9.... Read more

Immunology

view channel
Image: The findings were based on patients from the ADAURA clinical trial of the targeted therapy osimertinib for patients with NSCLC with EGFR-activated mutations (Photo courtesy of YSM Multimedia Team)

Post-Treatment Blood Test Could Inform Future Cancer Therapy Decisions

In the ongoing advancement of personalized medicine, a new study has provided evidence supporting the use of a tool that detects cancer-derived molecules in the blood of lung cancer patients years after... Read more

Microbiology

view channel
Image: Schematic representation illustrating the key findings of the study (Photo courtesy of UNIST)

Breakthrough Diagnostic Technology Identifies Bacterial Infections with Almost 100% Accuracy within Three Hours

Rapid and precise identification of pathogenic microbes in patient samples is essential for the effective treatment of acute infectious diseases, such as sepsis. The fluorescence in situ hybridization... Read more

Industry

view channel
Image: Tumor-associated macrophages visualized using the Multiomic LS Assay (Photo courtesy of ACD)

Leica Biosystems and Bio-Techne Expand Spatial Multiomic Collaboration

Bio-Techne Corporation (Minneapolis, MN, USA) has expanded the longstanding partnership between its spatial biology brand, Advanced Cell Diagnostics (ACD, Newark, CA, USA), and Leica Biosystems (Nussloch,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.